PYLARIFY TRUVU Drug Patent Profile

Which patents cover Pylarify Truvu, and what generic alternatives are available?

Pylarify Truvu is a drug marketed by Aphelion and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and eighteen patent family members in twenty-seven countries.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Two suppliers are listed for this compound. Additional details are available on the piflufolastat f-18 profile page.

DrugPatentWatch^® Generic Entry Outlook for Pylarify Truvu

Pylarify Truvu was eligible for patent challenges on May 26, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 7, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for PYLARIFY TRUVU

International Patents:	118
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PYLARIFY TRUVU

PYLARIFY TRUVU is protected by six US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aphelion	PYLARIFY TRUVU	piflufolastat f-18	SOLUTION;INTRAVENOUS	220089-001	Mar 6, 2026		RX	Yes	Yes			Y	Y
Aphelion	PYLARIFY TRUVU	piflufolastat f-18	SOLUTION;INTRAVENOUS	220089-001	Mar 6, 2026		RX	Yes	Yes
Aphelion	PYLARIFY TRUVU	piflufolastat f-18	SOLUTION;INTRAVENOUS	220089-001	Mar 6, 2026		RX	Yes	Yes			Y	Y

International Patents for PYLARIFY TRUVU

When does loss-of-exclusivity occur for PYLARIFY TRUVU?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Japan

Poland

Portugal

Slovenia

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PYLARIFY TRUVU around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3026889
Canada	3240630
China	109563038

Supplementary Protection Certificates for PYLARIFY TRUVU

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2318366	LUC00323	Luxembourg		PRODUCT NAME: PIFLUFOLASTAT (18F) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/23/1746 20230725
2318366	CR 2023 00032	Denmark		PRODUCT NAME: PIFLUFOLASTAT (18F) ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/23/1746 20230725
2318366	C202330040	Spain		PRODUCT NAME: PIFLUFOLASTATO (18F) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1746; DATE OF AUTHORISATION: 20230724; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1746; DATE OF FIRST AUTHORISATION IN EEA: 20230724

Last updated: May 2, 2026

PYLARIFY TRUVU (Pluvicto/PSMA-targeted imaging-therapy brand family): Investment scenario and fundamentals analysis

What is PYLARIFY TRUVU and what is the investable asset?

PYLARIFY TRUVU is a PSMA-targeted radiopharmaceutical imaging and/or therapeutic platform brand positioned around prostate cancer diagnosis and disease management using PSMA (prostate-specific membrane antigen) targeting. In practical investment terms, the investable asset is the commercial rights to the brand plus the underlying IP and supply chain for PSMA-targeted radiopharmaceutical production, including radiochemistry know-how, formulation, manufacturing scale, and site qualification.

Investable revenue drivers in this category are:

• Patient volumes in the prostate cancer continuum (initial staging, biochemical recurrence, metastasis workup, treatment selection)
• Reimbursement and uptake in nuclear medicine and oncology settings
• Competition intensity within PSMA radioligand imaging and PSMA-targeted radioligand therapy
• Supply constraints tied to radiochemistry, generator/production logistics, and radiopharmacy network capacity
• Regulatory expansion across indications and geographies

Where does the product sit in the PSMA radioligand value chain?

PYLARIFY TRUVU fits into a broader PSMA radiopharmaceutical ecosystem that typically spans:

1. PSMA-targeted imaging (diagnostic confirmation and staging)
2. PSMA-targeted therapy (theranostic pairing with the imaging agent)
3. Radiopharmacy operations (site qualification, cold chain where relevant, batch release)
4. Oncology pathway adoption (integration into urology and medical oncology care pathways)

For investors, the key question is whether PYLARIFY TRUVU behaves more like:

• An imaging franchise (faster adoption cycles, procedure-based reimbursement, broad eligibility), or
• A therapy franchise (slower adoption cycles, higher reimbursement per course, stronger clinical differentiation requirements)

The “TRUVU” styling is generally used in brands that map to imaging-centric workflow. That implies the near-term financial profile often tracks imaging utilization and protocol adoption more than therapy sequencing. The valuation therefore depends on coverage and protocol inclusion rather than only tumor response endpoints.

What are the core fundamentals shaping adoption?

For a PSMA-targeted radiopharmaceutical brand family, fundamentals converge on four measurable levers.

1) Clinical differentiation and endpoint credibility

• Diagnostic performance (lesion detection rates, sensitivity by PSA and prior therapy status)
• Theranostic alignment (if paired with therapy, imaging-to-treatment selection relevance)
• Safety profile (renal exposure, salivary/other off-target signal, hematologic effects if therapy-adjacent)

Investors model these as:

• Adoption probability in guideline-driven pathways
• Persistence of use across recurrence strata
• Relative switching cost versus alternative PSMA imaging/therapy agents

2) Supply reliability and radiopharmacy scalability

A PSMA radiopharmaceutical lives or dies on operational capacity. Key fundamentals include:

• Ability to manufacture consistently and release on schedule
• Network expansion to hospitals/radiopharmacies
• Dose standardization and QC pass rates
• Logistics that protect schedule-dependent imaging and treatment slots

In this space, “pipeline value” is often constrained by operational throughput more than by clinical demand.

3) Reimbursement and payer coverage

Near-term economics are driven by:

• Coverage status for prostate cancer staging/recurrence workup
• Site-of-care reimbursement (hospital outpatient, imaging center, nuclear medicine practice)
• Prior authorization patterns and utilization management
• Distinct billing codes (where applicable) and coding stability over time

Investors should underwrite real-world net price and coverage breadth, not only list price.

4) Competition intensity

Competition typically includes:

• Competing PSMA imaging agents
• Alternative imaging modalities for staging (CT/MRI/bone scan patterns, PET alternatives)
• Competing theranostic strategies where imaging drives therapy allocation

The critical metric is expected market share trajectory based on clinical protocols and coverage.

---

Investment scenario: Base case, bull case, bear case

What outcomes are plausible for PYLARIFY TRUVU over a 3 to 5 year horizon?

Without product-level financials, this analysis frames the investment scenario using radiopharmaceutical mechanics: adoption, throughput, and payer pull-through.

Base case (most likely)

• Adoption remains steady in PSMA imaging-eligible patient flows
• Growth is constrained by supply and site capacity, not demand
• Coverage expands gradually via payer policy updates and provider experience
• Market share gains come from workflow integration rather than label breakthroughs

Financial shape:

• Revenue growth is volume-driven
• Margin profile depends on radiochemistry costs, QC, yield, and radiopharmacy throughput utilization

Bull case (upside)

• Faster protocol adoption in recurrence and staging pathways
• Broader payer coverage with fewer utilization restrictions
• Supply network expansion outpaces demand, driving higher capture rates
• Potential label expansions broaden eligible patient strata

Financial shape:

• Acceleration from improved access and higher average volumes per site
• Margin improves with manufacturing scale and reduced per-dose QC overhead

Bear case (downside)

• Competitive PSMA agents displace portions of the workup pathway
• Payer coverage tightens, requiring additional evidence thresholds
• Supply delays or radiopharmacy qualification bottlenecks slow throughput
• Execution issues lead to missed appointment slots and lost referral share

Financial shape:

• Revenue growth flattens or declines
• Higher cost of supply per dose and idle capacity pressure margins

---

Market and commercial adoption

How should investors underwrite TAM and uptake for PSMA imaging/therapy brands?

Underwriting works best when done by patient-pathway mapping:

Key TAM drivers

• Prostate cancer incidence and recurrence prevalence
• Number of eligible patients by PSA and prior treatment state
• Imaging utilization rate for PSMA-eligible workflows
• Share captured by PSMA PET relative to competing imaging

Uptake constraints

• Radiopharmacy geography and referral radius
• Physician ordering habits and facility readiness
• Payer pre-approval burden

What matters most

• The installed base of imaging sites and their throughput
• Provider and payer consensus on best-use indications

For investors, the most actionable commercial question is:

• Will PYLARIFY TRUVU become a default ordering choice in the workup pipeline, or a substitute used when other imaging fails?

---

Competitive positioning

What are the likely competitive vectors?

In PSMA radiopharmaceuticals, competitive advantage typically comes from:

• Higher diagnostic confidence at clinically relevant PSA ranges
• More favorable safety and handling profiles that reduce operational friction
• Protocol inclusion in radiology/nuclear medicine workflows
• Supply reliability that avoids missed schedules
• Theranostic ecosystem strength if the brand family supports treatment selection

Investors should judge PYLARIFY TRUVU on:

• Likely switching risk based on clinical evidence and practical workflow
• Differentiation that payers will recognize when setting coverage

---

Manufacturing and supply chain economics

What cost and capacity fundamentals drive margins?

Radiopharmaceutical economics are operational.

Key unit economics drivers

• Radiochemical yield and batch success rate
• QC testing throughput and pass/fail costs
• Dose standardization and waste
• Site dosing frequency and scheduling utilization
• Staff qualification and inventory carrying costs for radiologic materials

Capacity and timing

• Qualification of radiopharmacies and imaging centers
• Lead times for production and distribution
• Backlogs that can force appointment deferrals

Underwriting should model:

• Revenue ramp versus capacity ramp
• Cost curve benefits from higher utilization and fewer batch reworks

---

Regulatory and pipeline risk

What are the regulatory risks that matter for investment value?

For radiopharmaceutical brands, the main regulatory risks usually sit in:

• Expanded label indications (new patient groups)
• Manufacturing compliance and batch consistency
• Post-approval commitments affecting operational timelines
• Safety signal management in broader use settings

Investors should treat label expansion as a growth catalyst but underwrite it against operational readiness and evidence sufficiency.

---

Scenario-based valuation framework

How should investors translate fundamentals into an investment model?

A usable model in this segment breaks value creation into:

• Volume CAGR by site expansion and payer adoption
• Net price by coverage and utilization management
• Gross margin by radiochemistry unit economics and batch success
• Operating leverage from fixed-cost absorption across manufacturing and radiopharmacy operations
• Cash conversion shaped by working capital for production inputs and distribution cycles

A practical scenario approach is:

1. Set a site penetration trajectory
2. Apply throughput per site assuming scheduling capacity and referral patterns
3. Apply payer coverage transitions (utilization management loosening or tightening)
4. Apply competition displacement as a share loss or slower capture rate
5. Convert into revenue and margin paths using supply cost curves

What to watch each quarter

• Doses shipped and delivered (proxy for demand capture and supply performance)
• Site onboarding pace and appointment availability metrics
• Payer changes in policy coverage that affect net price and utilization

---

Key Takeaways

• PYLARIFY TRUVU is an investable radiopharmaceutical brand franchise whose value is driven primarily by PSMA pathway adoption, payer coverage, and radiopharmacy throughput, not only clinical headlines.
• The base case likely hinges on steady imaging utilization growth moderated by supply and site capacity.
• Bull case outcomes require faster protocol inclusion and payer coverage expansion plus scaling operations without quality or schedule disruptions.
• Bear case outcomes typically stem from competitive displacement, payer tightening, or operational bottlenecks that reduce delivered doses.
• A valuation model should be built around volume, net price, and supply cost curve with scenario-based sensitivities tied to coverage and capacity ramps.

---

FAQs

1. What is the main revenue driver for PSMA-targeted radiopharmaceutical brands like PYLARIFY TRUVU?
   Delivered dose volume tied to patient eligibility and PSMA pathway ordering habits, then moderated by payer coverage and utilization management.

2. What determines whether the brand scales quickly?
   Radiopharmacy onboarding, manufacturing consistency, and appointment scheduling capacity that prevent demand from being capped by throughput.

3. How do payers influence investment outcomes?
   Through coverage breadth, prior authorization requirements, and coding practices that determine net price and the portion of eligible patients who actually get scanned.

4. What competitive factors matter most in this category?
   Diagnostic confidence that drives clinician preference, operational reliability that preserves referral share, and coverage positioning that sets utilization.

5. What is the highest-impact risk for financial performance?
   Operational execution risk that reduces delivered doses or increases per-dose supply costs via batch variability and underutilized capacity.

---

References

[1] FDA. Drug Approval Packages (search portal for radiopharmaceuticals and related label documents). U.S. Food and Drug Administration.
[2] EANM. Guidance and position statements on PSMA PET imaging in prostate cancer (scope and clinical use discussions). European Association of Nuclear Medicine.
[3] NCCN Guidelines. Prostate Cancer (updates covering imaging workup and PSMA PET usage in recurrence/staging pathways). National Comprehensive Cancer Network.
[4] SNMMI. Clinical practice guidance for PSMA PET and nuclear medicine workflow considerations. Society of Nuclear Medicine and Molecular Imaging.
[5] CMS. Medicare Coverage and Payment policies relevant to PET imaging and radiopharmaceutical-associated billing frameworks (policy and reimbursement changes). Centers for Medicare & Medicaid Services.